Anthera Pharmaceuticals Appoints Dr. Philip Sager to Board of Directors

HAYWARD, Calif., June 13, 2014

Dr. Sager is a Fellow of the American College of Cardiology, a Fellow of the American Heart Association and a Fellow of the Heart Rhythm Society.  Dr. Sager has served as a Consulting Professor of Medicine at the Stanford University School of Medicine since 2013, a Full Voting Member of the United States Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee since 2011, a private pharmaceutical, device and diagnostics consultant since 2010 and Member of the Scientific Programs Committee, the Scientific Oversight Committee, and the Executive Committee of the Cardiac Safety Research Consortium since 2006, serving as Chair of the Scientific Programs Committee and Scientific Oversight Committee at various times.    From 2009 through 2010 Dr. Sager was Vice President, Clinical Research and Head, CV/Metabolic Development for Gilead Sciences, a biotechnology company.  Dr. Sager holds an M.D. from Yale University School of Medicine and B.S. degrees in chemistry and biology from the Massachusetts Institute of Technology

"We are pleased to welcome Dr. Sager to our board of directors. Philip's extensive global regulatory expertise and industry experience in drug development will offer us a great perspective as we continue to navigate the evolving FDA regulatory landscape," said Dr. Chris Henney, Chairman of Anthera Pharmaceuticals. "We look forward to taking advantage of his insight and strategic guidance as we further advance Anthera's late-stage clinical trials."

"Anthera is entering an exciting time as it accelerates its clinical studies in lupus and IgA nephropathy," said Dr. Sager. "I look forward to working with the Anthera Board and experienced senior management team as they execute the clinical and regulatory activities necessary to further advance the blisibimod development program."

Effective at Anthera's Annual General Meeting held on June 10, 2014 Dr. Bogdan Dziurzynski has retired from Anthera's Board of Directors.  Dr. Dziurzynski joined the Anthera Board of Directors in 2012.

"Bogdan's guidance in navigating a multitude of challenges has been invaluable over the past two years," said Dr. Chris Henney.  "The management team and Board of Directors are grateful for his guidance and wish him all the best."

About Anthera Pharmaceuticals